Tags

Type your tag names separated by a space and hit enter

CSF biomarkers for mild cognitive impairment.

Abstract

A correct clinical diagnosis of Alzheimer's disease (AD) early in the course of the disease is of importance to initiate symptomatic treatment with acetylcholine esterase inhibitors, and will be even more important when disease-arresting drugs, such as beta-sheet breakers or gamma-secretase inhibitors, will reach the clinic. However, there is no clinical method to determine if a patient with mild cognitive impairment (MCI) has incipient AD, i.e. will progress to AD with dementia, or have a benign form of MCI without progression. Thus, there is a great clinical need for diagnostic biomarkers to identify incipient AD in MCI cases. Three cerebrospinal fluid (CSF) biomarkers; total-tau (T-tau), phospho-tau (P-tau) and the 42 amino acid form of beta-amyloid (Abeta42) have been evaluated in numerous scientific papers. These CSF markers have high sensitivity to differentiate early and incipient AD from normal ageing, depression, alcohol dementia and Parkinson's disease, but lower specificity against other dementias, such as frontotemporal and Lewy body dementia. However, if the CSF biomarkers are used in the right clinical context, i.e. together with the cumulative information from the clinical examination, standard laboratory tests and brain-imaging techniques [single photon emission tomography (SPECT) and magnetic resonance tomography (MRT) scans], they may have a role in the clinical evaluation of MCI cases.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    Department of Clinical Neuroscience, Section of Experimental Neuroscience, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden. kaj.blennow@neuro.gu.se

    Source

    Journal of internal medicine 256:3 2004 Sep pg 224-34

    MeSH

    Aged
    Alzheimer Disease
    Amyloid beta-Peptides
    Biomarkers
    Cognition Disorders
    Disease Progression
    Humans
    tau Proteins

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    15324365

    Citation

    Blennow, K. "CSF Biomarkers for Mild Cognitive Impairment." Journal of Internal Medicine, vol. 256, no. 3, 2004, pp. 224-34.
    Blennow K. CSF biomarkers for mild cognitive impairment. J Intern Med. 2004;256(3):224-34.
    Blennow, K. (2004). CSF biomarkers for mild cognitive impairment. Journal of Internal Medicine, 256(3), pp. 224-34.
    Blennow K. CSF Biomarkers for Mild Cognitive Impairment. J Intern Med. 2004;256(3):224-34. PubMed PMID: 15324365.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - CSF biomarkers for mild cognitive impairment. A1 - Blennow,K, PY - 2004/8/25/pubmed PY - 2004/12/16/medline PY - 2004/8/25/entrez SP - 224 EP - 34 JF - Journal of internal medicine JO - J. Intern. Med. VL - 256 IS - 3 N2 - A correct clinical diagnosis of Alzheimer's disease (AD) early in the course of the disease is of importance to initiate symptomatic treatment with acetylcholine esterase inhibitors, and will be even more important when disease-arresting drugs, such as beta-sheet breakers or gamma-secretase inhibitors, will reach the clinic. However, there is no clinical method to determine if a patient with mild cognitive impairment (MCI) has incipient AD, i.e. will progress to AD with dementia, or have a benign form of MCI without progression. Thus, there is a great clinical need for diagnostic biomarkers to identify incipient AD in MCI cases. Three cerebrospinal fluid (CSF) biomarkers; total-tau (T-tau), phospho-tau (P-tau) and the 42 amino acid form of beta-amyloid (Abeta42) have been evaluated in numerous scientific papers. These CSF markers have high sensitivity to differentiate early and incipient AD from normal ageing, depression, alcohol dementia and Parkinson's disease, but lower specificity against other dementias, such as frontotemporal and Lewy body dementia. However, if the CSF biomarkers are used in the right clinical context, i.e. together with the cumulative information from the clinical examination, standard laboratory tests and brain-imaging techniques [single photon emission tomography (SPECT) and magnetic resonance tomography (MRT) scans], they may have a role in the clinical evaluation of MCI cases. SN - 0954-6820 UR - https://www.unboundmedicine.com/medline/citation/15324365/CSF_biomarkers_for_mild_cognitive_impairment_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0954-6820&date=2004&volume=256&issue=3&spage=224 DB - PRIME DP - Unbound Medicine ER -